Myocardial Expression Analysis of Osteopontin and Its Splice Variants in Patients Affected by End-Stage Idiopathic or Ischemic Dilated Cardiomyopathy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Aug 2

PMID 27479215

Citations 10

Authors

Manuela Cabiati

Benedetta Svezia

Marco Matteucci

Luca Botta

Angela Pucci

Mauro Rinaldi

Chiara Caselli

Vincenzo Lionetti

Silvia Del Ry

Affiliations

Soon will be listed here.

Abstract

Osteopontin (OPN) is a phosphoglycoprotein of cardiac extracellular matrix and it is still poorly defined whether its expression changes in failing heart of different origin. The full-length OPN-a and its isoforms (OPN-b, OPN-c) transcriptomic profile were evaluated in myocardium of patients with dilated or ischemic cardiomyopathy (DCM n = 8; LVEF% = 17.5±3; ICM n = 8; LVEF% = 19.5±5.2) and in auricle of valvular patients (VLP n = 5; LVEF%≥50), by Real-time PCR analysis. OPN-a and thrombin mRNA levels resulted significantly higher in DCM compared to ICM patients (DCM:31.3±7.4, ICM:2.7±1.1, p = 0.0002; DCM:19.1±4.9, ICM:5.4±2.2, p = 0.007, respectively). Although both genes' mRNA levels increased in patients with LVEF<50% (DCM+ICM) with respect to VLP with LVEF>50%, a significant increase in OPN (p = 0.0004) and thrombin (p = 0.001) expression was observed only in DCM. In addition, a correlation between OPN-a and thrombin was found in patients with LVEF<50% (r = 0.6; p = 0.003). The mRNA pattern was confirmed by OPN-a cardiac protein concentration (VLP:1.127±0.26; DCM:1.29±0.22; ICM:1.00±0.077 ng/ml). The OPN splice variants expression were detectable only in ICM (OPN-b: 0.357±0.273; OPN-c: 0.091±0.033) and not in DCM patients. A significant correlation was observed between collagen type I, evaluated by immunohistochemistry analysis, and both OPN-a mRNA expression (r = 0.87, p = 0.002) and OPN protein concentrations (r = 0.77, p = 0.016). Concluding, OPN-a and thrombin mRNA resulted dependent on the origin of heart failure while OPN-b and OPN-c highlighted a different expression for DCM and ICM patients, suggesting their correlation with different clinical-pathophysiological setting.

Citing Articles

Relationships between Osteopontin, Osteoprotegerin, and Other Extracellular Matrix Proteins in Calcifying Arteries.

Kuzan A, Chwilkowska A, Maksymowicz K, Abramczyk U, Gamian A Biomedicines. 2024; 12(4).

PMID: 38672202 PMC: 11048129. DOI: 10.3390/biomedicines12040847.

Extracellular Targets to Reduce Excessive Scarring in Response to Tissue Injury.

Fertala J, Wang M, Rivlin M, Beredjiklian P, Abboud J, Arnold W Biomolecules. 2023; 13(5).

PMID: 37238628 PMC: 10216402. DOI: 10.3390/biom13050758.

The Intracellular and Secreted Sides of Osteopontin and Their Putative Physiopathological Roles.

Bastos A, Gomes A, Silva G, Emerenciano M, Ferreira L, Gimba E Int J Mol Sci. 2023; 24(3).

PMID: 36769264 PMC: 9917417. DOI: 10.3390/ijms24032942.

Clinical and Molecular Implications of Osteopontin in Heart Failure.

Mamazhakypov A, Sartmyrzaeva M, Sarybaev A, Schermuly R, Sydykov A Curr Issues Mol Biol. 2022; 44(8):3573-3597.

PMID: 36005141 PMC: 9406846. DOI: 10.3390/cimb44080245.

Osteopontin in Cardiovascular Diseases.

Shirakawa K, Sano M Biomolecules. 2021; 11(7).

PMID: 34356671 PMC: 8301767. DOI: 10.3390/biom11071047.

References

Francis G, Greenberg B, Hsu D, Jaski B, Jessup M, LeWinter M . ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. J Am Coll Cardiol. 2010; 56(5):424-53. DOI: 10.1016/j.jacc.2010.04.014. View

Del Ry S, Giannessi D, Maltinti M, Cabiati M, Prontera C, Iervasi A . Increased plasma levels of osteopontin are associated with activation of the renin-aldosterone system and with myocardial and coronary microvascular damage in dilated cardiomyopathy. Cytokine. 2009; 49(3):325-30. DOI: 10.1016/j.cyto.2009.11.018. View

Singh K, Sirokman G, Communal C, Robinson K, Conrad C, Brooks W . Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 1999; 33(2):663-70. DOI: 10.1161/01.hyp.33.2.663. View

Breyne J, Juthier F, Corseaux D, Marechaux S, Zawadzki C, Jeanpierre E . Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis. 2010; 213(2):369-76. DOI: 10.1016/j.atherosclerosis.2010.07.047. View

Lionetti V, Matteucci M, Ribezzo M, Silvestre D, Brambilla F, Agostini S . Regional mapping of myocardial hibernation phenotype in idiopathic end-stage dilated cardiomyopathy. J Cell Mol Med. 2014; 18(3):396-414. PMC: 3955147. DOI: 10.1111/jcmm.12198. View

Herpel E, Pritsch M, Koch A, Dengler T, Schirmacher P, Schnabel P . Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy. Histopathology. 2006; 48(6):736-47. DOI: 10.1111/j.1365-2559.2006.02398.x. View

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

Opie L, Commerford P, Gersh B, Pfeffer M . Controversies in ventricular remodelling. Lancet. 2006; 367(9507):356-67. DOI: 10.1016/S0140-6736(06)68074-4. View

Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A . Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2009; 1(1):43-9. DOI: 10.1161/CIRCHEARTFAILURE.107.746172. View

10.

Grassinger J, Haylock D, Storan M, Haines G, Williams B, Whitty G . Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood. 2009; 114(1):49-59. DOI: 10.1182/blood-2009-01-197988. View

11.

Grau J, Poggio P, Sainger R, Vernick W, Seefried W, Branchetti E . Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann Thorac Surg. 2011; 93(1):79-86. PMC: 3269243. DOI: 10.1016/j.athoracsur.2011.08.036. View

12.

Christensen B, Schack L, Klaning E, Sorensen E . Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D. J Biol Chem. 2010; 285(11):7929-37. PMC: 2832943. DOI: 10.1074/jbc.M109.075010. View

13.

Dashkevich A, Bloch W, Antonyan A, Goebel H, Fries J, Schlensak C . Immunohistochemical study of remodeling of myocardial lymphatic and blood microvascular structures in terminal heart failure: differences between ischemic and dilated cardiomyopathy. Lymphology. 2011; 43(3):110-7. View

14.

Kostin S, Pool L, Elsasser A, Hein S, Drexler H, Arnon E . Myocytes die by multiple mechanisms in failing human hearts. Circ Res. 2003; 92(7):715-24. DOI: 10.1161/01.RES.0000067471.95890.5C. View

15.

Del Ry S, Cabiati M, Lionetti V, Aquaro G, Martino A, Mattii L . Pacing-induced regional differences in adenosine receptors mRNA expression in a swine model of dilated cardiomyopathy. PLoS One. 2012; 7(10):e47011. PMC: 3470544. DOI: 10.1371/journal.pone.0047011. View

16.

Del Ry S, Cabiati M, Lionetti V, Emdin M, Recchia F, Giannessi D . Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart. Peptides. 2008; 29(12):2208-15. DOI: 10.1016/j.peptides.2008.09.005. View

17.

Ashkar S, Weber G, Panoutsakopoulou V, Sanchirico M, Jansson M, Zawaideh S . Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000; 287(5454):860-4. DOI: 10.1126/science.287.5454.860. View

18.

Smith L, Cheung H, Ling L, Chen J, Sheppard D, Pytela R . Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem. 1996; 271(45):28485-91. View

19.

Johnson R, Leopold J, Loscalzo J . Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006; 99(10):1044-59. DOI: 10.1161/01.RES.0000249379.55535.21. View

20.

Soejima H, Irie A, Fukunaga T, Oe Y, Kojima S, Kaikita K . Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ J. 2007; 71(12):1879-84. DOI: 10.1253/circj.71.1879. View